ATXI 2.26 -46% Avenue Therapeutics Receives Complete Response Letter From FDA For IV Tramadol; CRL States That 'the delayed and unpredictable onset of analgesia with IV tramadol does not support its benefit as a monotherapy to treat patients in acute pain' Benzinga
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.